Hydroxypropyl-β-cyclodextrin (HP-β-CD) is being explored as excipient for administration of poorly soluble NCE's in pediatrics. In support of pharmaceutical development, non-clinical studies were
performed to investigate whether oral and intravenous administration of HP-β-CD showed a different response in juvenile rats versus adult rats.